AstraZeneca invests in Imperial’s self-amplifying RNA tech with eye on future drugs
AstraZeneca already produces an adenoviral vector Covid-19 vaccine, and is emphasising the potential of the self-amplifying RNA technology in novel therapeutic programmes beyond the coronavirus pandemic.